Divyam Pharmaceuticals

• Broad-Spectrum Hepatitis C Treatment: This combination is effective against all major genotypes (1 to 6) of the Hepatitis C virus, making it a pan-genotypic antiviral regimen.

• Dual Action Formula: Sofosbuvir blocks the NS5B RNA polymerase, and Velpatasvir inhibits the NS5A protein, both essential for viral replication and survival.

• Simple Dosing Regimen: Administered as one tablet once daily, with or without food, for a typical course of 12 weeks depending on the patient's condition.

• High Success Rate and Tolerability: Offers cure rates above 95% in most patients, with commonly mild side effects like fatigue, headache, and nausea.

• Fixed-Dose Combination for HIV Treatment: This tablet combines three antiretroviral drugs used together to manage HIV-1 infection effectively in adults and adolescents.

• Mechanism of Action:

  • Tenofovir & Lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs)

  • Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI)
    Together, they block the reverse transcriptase enzyme, preventing the virus from replicating.

• Once-Daily Oral Dosing: Usually taken once daily, preferably at bedtime to reduce central nervous system side effects caused by Efavirenz (like dizziness or vivid dreams).

• Improves Viral Suppression: When taken consistently, this combination helps reduce viral load to undetectable levels and boosts immune function, thereby delaying disease progression.

• Dual PPAR Agonist Action
  Saroglitazar activates both PPAR-α and PPAR-γ receptors, improving lipid metabolism and insulin sensitivity to help manage diabetic dyslipidemia effectively.

• Comprehensive Lipid Control
  Significantly reduces triglycerides and LDL cholesterol while moderately increasing HDL cholesterol—helpful in patients with type 2 diabetes and elevated lipid levels.

• Metabolic Benefits
  Lowers blood sugar and improves insulin resistance, offering added benefits beyond lipid control for diabetic patients.

• Once-Daily Oral Dose
  Designed for convenience and adherence with a single tablet taken daily, often alongside standard diabetic treatments like metformin or statins.

• Immunosuppressive Agent: Used to prevent organ rejection in kidney, heart, or liver transplant patients by suppressing the immune system.

• Active Form: It is a prodrug that converts to mycophenolic acid, which inhibits T and B lymphocyte proliferation.

• Dosage: Typically prescribed at 1,000 mg twice daily (2,000 mg total per day) in adults, often in combination with other immunosuppressants.

• Precautions: Requires monitoring of white blood cell counts and infection risks; contraindicated in pregnancy due to teratogenic effects.

• Antiviral Medication: Used primarily for the treatment of chronic hepatitis B virus (HBV) infection and also as part of combination therapy for HIV.

• Improved Safety Profile: Compared to its predecessor (Tenofovir disoproxil fumarate), it has less impact on kidneys and bone mineral density, making it safer for long-term use.

• Once-Daily Dosing: Typically taken once daily, with or without food, and often prescribed as a single agent or included in fixed-dose combination therapies.

• Mechanism of Action: It is a prodrug of tenofovir that becomes active inside cells, inhibiting viral reverse transcriptase and preventing replication of the virus.

• Pan-Genotypic Hepatitis C Treatment: Effective against all major genotypes (1–6) of the Hepatitis C virus, making it suitable for a wide range of patients.

• Dual Antiviral Mechanism: Sofosbuvir inhibits the viral RNA polymerase (NS5B), while Velpatasvir blocks the NS5A protein, together preventing viral replication and spread.

• Convenient Dosing: Taken as a single tablet once daily, with or without food, typically for 12 weeks depending on the patient's condition.

• High Cure Rates: Offers sustained virologic response (SVR) rates of over 95%, with minimal side effects like headache, fatigue, and nausea.

• Antiviral Agent: Used to treat chronic Hepatitis B and HIV-1 infection, often as part of a combination therapy in antiretroviral treatment regimens.

• NRTI Class: Belongs to the nucleoside reverse transcriptase inhibitor (NRTI) group, which works by blocking an enzyme essential for viral replication.

• Once-Daily Oral Dose: Typically taken once a day, with or without food, depending on the combination and the patient's condition.

• Potential Side Effects: May include kidney toxicity, reduced bone mineral density, nausea, and fatigue; regular renal and bone health monitoring is recommended.

• Targeted Cancer Therapy: Regorafenib is a multi-kinase inhibitor used to treat advanced cancers such as metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma after failure of previous treatments.

• Tablet Strength and Dose: Available as 40 mg tablets; the standard dose is 160 mg once daily (i.e., 4 tablets) for 21 days followed by a 7-day break in a 28-day treatment cycle.

• Administration Guidelines: Tablets should be taken once daily after a low-fat meal (less than 30% fat content), and must be swallowed whole—do not crush or chew.

• Adverse Effects: Common side effects include fatigue, hand–foot skin reaction, diarrhea, hypertension, and liver toxicity. Close monitoring is needed during treatment.

• Dose Adjustment: Dose may be reduced in 40 mg steps depending on the patient’s tolerance and side effect profile, with a minimum effective dose of 80 mg per day.

Description
Gallstone dissolution & prevention: Contains ursodeoxycholic acid (300 mg) to dissolve cholesterol-rich gallstones in a functioning gallbladder and help prevent new ones, particularly in patients undergoing rapid weight loss 
Liver-protective effects: Used in primary biliary cholangitis and certain liver conditions (e.g., cystic fibrosis-related liver disease), as it improves bile flow, reduces toxic bile acid buildup, and supports liver function 
Dosing regimen: Typically 8–10 mg/kg/day divided doses for gallstones; for prevention, 300 mg twice daily; in PBC, 13–15 mg/kg/day in 2–4 divided doses. Treatment may continue for months, with regular ultrasound monitoring 
 
Side effects & precautions: Common side effects include diarrhea, nausea, abdominal pain, headache, rash, and pruritus. Not suitable for calcified stones, gallbladder inflammation or obstruction, or severe liver disease; use cautiously during pregnancy and breastfeeding.

• Triple Antiretroviral Combination: Contains Lamivudine (150 mg), Zidovudine (300 mg), and Nevirapine (200 mg) used together for the effective management of HIV-1 infection.

• Mechanism of Action: Each component works at different stages of the HIV life cycle—Lamivudine and Zidovudine are NRTIs (nucleoside reverse transcriptase inhibitors), and Nevirapine is an NNRTI (non-nucleoside reverse transcriptase inhibitor).

• Treatment Use: Indicated for adults and adolescents in combination therapy for HIV; helps reduce viral load and increase CD4 cell counts.

• Dosing: Usually administered twice daily after an initial lead-in dose of Nevirapine to reduce the risk of rash or liver toxicity.

• Precautions: Regular monitoring of liver function, blood counts (due to risk of anemia and neutropenia), and signs of hypersensitivity is required. Not recommended in patients with significant hepatic impairment.

• Non‑steroidal mineralocorticoid receptor antagonist
  Selectively blocks MR receptors to reduce inflammation and fibrosis in the kidneys and heart of patients with type 2 diabetes and CKD 

• Precision dosing & tablet design
  Each light-pink, oval, film-coated tablet contains 10 mg finerenone with lactose; ideal starting dose for patients with moderate renal function (eGFR 25–60) 

• Once-daily oral administration
  Taken once daily (with or without food), making it convenient for long-term therapy; dose is adjusted based on eGFR and serum potassium levels .

• Requires potassium and renal monitoring
  Strong risk of hyperkalemia (≈18%), especially in CKD—mandatory monitoring of serum potassium and eGFR at baseline, 4 weeks, and periodically thereafter

• Cancer Treatment: Sorafenib is primarily used to treat advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and differentiated thyroid carcinoma unresponsive to radioactive iodine treatment.

• Multi-Kinase Inhibitor: It targets multiple protein kinases involved in tumor cell proliferation and angiogenesis (blood vessel growth), effectively slowing tumor growth.

• Oral Administration: Taken by mouth, typically twice daily on an empty stomach (1 hour before or 2 hours after meals), as per doctor’s prescription.

• Common Side Effects: Includes fatigue, diarrhea, hand-foot skin reaction, high blood pressure, and loss of appetite; regular monitoring is required during treatment.